Madison Investment Advisors LLC Purchases Shares of 27,684 Merck & Co., Inc. (NYSE:MRK)

Madison Investment Advisors LLC purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 27,684 shares of the company’s stock, valued at approximately $2,754,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRK. Franklin Resources Inc. raised its position in shares of Merck & Co., Inc. by 12.9% in the 3rd quarter. Franklin Resources Inc. now owns 16,049,161 shares of the company’s stock worth $1,759,800,000 after acquiring an additional 1,836,505 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of Merck & Co., Inc. by 1.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 1,902,509 shares of the company’s stock worth $189,262,000 after acquiring an additional 35,525 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 2.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 18,807,293 shares of the company’s stock worth $2,135,785,000 after acquiring an additional 514,060 shares in the last quarter. Littlejohn Financial Services Inc. bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $2,080,000. Finally, Thrivent Financial for Lutherans raised its position in shares of Merck & Co., Inc. by 3.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,837,354 shares of the company’s stock worth $208,649,000 after acquiring an additional 62,047 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Activity

In related news, Director Inge G. Thulin bought 2,833 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average cost of $88.25 per share, with a total value of $250,012.25. Following the acquisition, the director now owns 2,933 shares in the company, valued at $258,837.25. This trade represents a 2,833.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Cristal N. Downing sold 2,361 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares in the company, valued at approximately $628,864.60. This represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the subject of several research reports. Bank of America decreased their target price on Merck & Co., Inc. from $118.00 to $112.00 and set a “buy” rating for the company in a research report on Wednesday, February 5th. Citigroup decreased their target price on Merck & Co., Inc. from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Wednesday, February 5th. Truist Financial restated a “hold” rating and issued a $110.00 price target (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price target for the stock from $128.00 to $105.00 in a research note on Tuesday, February 18th. Finally, BMO Capital Markets cut their price target on Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 5th. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.12.

Check Out Our Latest Research Report on MRK

Merck & Co., Inc. Price Performance

NYSE MRK opened at $94.72 on Friday. The business’s fifty day moving average price is $93.57 and its 200-day moving average price is $101.99. The stock has a market capitalization of $239.27 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.77 and a beta of 0.35. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. Merck & Co., Inc. has a 1-year low of $81.04 and a 1-year high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $15.62 billion for the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. Merck & Co., Inc.’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.03 earnings per share. On average, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a share buyback program on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.42%. Merck & Co., Inc.’s payout ratio is 48.14%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.